Literature DB >> 7578614

Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method.

J Steinmetz1, P Tarallo, B Fournier, E Caces, G Siest.   

Abstract

An important collaborative study organized by the IFCC enabled the selection of international reference materials and the standardization of commercially available methods by the use of common calibrators. In this paper, we report the reference limits of apolipoprotein A-I and apolipoprotein B in a selected healthy French population. The apolipoprotein measurements were performed on BNA Behring using reagents and protocols supplied by the manufacturer: the standard sera were calibrated using the IFCC-WHO reference preparations (SP1 and SP3). In addition, the apolipoprotein B protocol was modified by the addition of a supplementary reagent to reduce the interference by lipaemic samples on immunonephelometric measurement. In a sample of 115 random serum samples, there was a decrease in mean concentration between non-standardized and standardized methods: -4.8% for apolipoprotein A-I and -4.7% for apolipoprotein B. The reference limits for apolipoprotein A-I are unaffected by gender between 4 and 14 years, thereafter vary with age and gender until 40 years and with gender alone between 40 and 60 years. For apolipoprotein B, the variation with gender is only significant between 30 and 49 years.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578614     DOI: 10.1515/cclm.1995.33.6.337

Source DB:  PubMed          Journal:  Eur J Clin Chem Clin Biochem        ISSN: 0939-4974


  3 in total

1.  Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease.

Authors:  Jan A Krikken; Ron T Gansevoort; Robin P F Dullaart
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

2.  Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.

Authors:  Carl J Fichtenbaum; Tzu-Min Yeh; Scott R Evans; Judith A Aberg
Journal:  J Clin Lipidol       Date:  2010 Jul-Aug       Impact factor: 4.766

3.  The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.

Authors:  Constantinos C Tellis; Eliza Moutzouri; Moses Elisaf; Robert L Wolfert; Alexandros D Tselepis
Journal:  J Lipid Res       Date:  2013-10-03       Impact factor: 5.922

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.